Your browser doesn't support javascript.
loading
Molecular characterization of disseminated pilocytic astrocytomas.
Gessi, M; Engels, A C; Lambert, S; Rothämel, T; von Hornstein, S; Collins, V P; Denkhaus, D; Gnekow, A; Pietsch, T.
Affiliation
  • Gessi M; Institute of Neuropathology, University of Bonn, Bonn, Germany.
  • Engels AC; Institute of Neuropathology, University of Bonn, Bonn, Germany.
  • Lambert S; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Rothämel T; Department of Forensic Medicine, University of Hannover Medical School, Hannover, Germany.
  • von Hornstein S; Department of Pediatric Oncology, Klinikum Augsburg, Augsburg, Germany.
  • Collins VP; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Denkhaus D; Institute of Neuropathology, University of Bonn, Bonn, Germany.
  • Gnekow A; Department of Pediatric Oncology, Klinikum Augsburg, Augsburg, Germany.
  • Pietsch T; Institute of Neuropathology, University of Bonn, Bonn, Germany.
Neuropathol Appl Neurobiol ; 42(3): 273-8, 2016 Apr.
Article in En | MEDLINE | ID: mdl-26084390
ABSTRACT

AIM:

Pilocytic astrocytomas represent the most common paediatric tumours of the central nervous system. Dissemination through the ventricular system occurs rarely in patients with pilocytic astrocytomas; however, it is more common in infants with diencephalic tumours, and is associated with a poor outcome. Despite histological similarities with classic pilocytic astrocytomas, it is still unclear whether disseminated pilocytic astrocytomas may have specific molecular features.

METHODS:

Seventeen disseminated pilocytic astrocytomas were investigated using the molecular inversion probe array and screened for the presence of gene fusions (KIAA1549-BRAF) and mutations (BRAF, RAS and FGFR1).

RESULTS:

Along with evidence of a constitutive MAPK activation in all cases, the molecular inversion probe array, fluorescence in situ hybridization analysis and mutational study revealed KIAA1549-BRAF fusions in 66% and BRAF(V600E) mutations in 5% of cases. No KRAS, HRAS, NRAS or FGFR1 mutations were found.

CONCLUSIONS:

disseminated pilocytic astrocytomas showed genetic features similar to classic pilocytic astrocytoma, including a similar incidence of KIAA1549-BRAF fusions, BRAF mutations and a stable genetic profile. Given common activation of the MAPK pathway, the use of specific inhibitors can be hypothesized for the treatment of disseminated pilocytic astrocytomas, along with standard chemo- and/or radiotherapy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Astrocytoma / Brain Neoplasms Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Neuropathol Appl Neurobiol Year: 2016 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Astrocytoma / Brain Neoplasms Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Neuropathol Appl Neurobiol Year: 2016 Type: Article Affiliation country: Germany